Peter A Forsyth
Overview
Explore the profile of Peter A Forsyth including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
101
Citations
3477
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Smalley I, Boire A, Brastianos P, Kluger H, Hernando-Monge E, Forsyth P, et al.
Pigment Cell Melanoma Res
. 2023 Aug;
37(1):51-67.
PMID: 37622466
Leptomeningeal disease (LMD) remains a major challenge in the clinical management of metastatic melanoma patients. Outcomes for patient remain poor, and patients with LMD continue to be excluded from almost...
12.
Khatri V, Mills M, Oliver D, Yu H, Vogelbaum M, Forsyth P, et al.
J Neurooncol
. 2023 Jul;
164(1):191-197.
PMID: 37490232
Purpose: HER2-positive breast cancer has a high risk of brain metastasis. Stereotactic radiosurgery (SRS) is standard of care for limited brain metastases. Tucatinib, a HER2-targeted tyrosine kinase inhibitor, has demonstrated...
13.
Chen Y, Jaffer M, Zhou L, Moslehi J, Forsyth P, Fecher L
Am Soc Clin Oncol Educ Book
. 2023 May;
43:e390594.
PMID: 37229626
The overall survival of advanced melanoma has improved dramatically. Immunotherapies, specifically checkpoint inhibitors, have played a large role in this improvement. These agents have also shown benefit in the adjuvant...
14.
Khaled M, Tarhini A, Forsyth P, Smalley I, Pina Y
Cancers (Basel)
. 2023 Mar;
15(6).
PMID: 36980770
Leptomeningeal disease (LMD) is a devastating complication caused by seeding malignant cells to the cerebrospinal fluid (CSF) and the leptomeningeal membrane. LMD is diagnosed in 5-15% of patients with systemic...
15.
Rubino S, Oliver D, Tran N, Vogelbaum M, Forsyth P, Yu H, et al.
Front Oncol
. 2022 Mar;
12:854402.
PMID: 35311078
Brain metastases are the most common form of brain cancer. Increasing knowledge of primary tumor biology, actionable molecular targets and continued improvements in systemic and radiotherapy regimens have helped improve...
16.
Mills M, King W, Soyano A, Pina Y, Czerniecki B, Forsyth P, et al.
J Neurooncol
. 2022 Mar;
157(2):249-269.
PMID: 35244835
Patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer are at a particularly high risk of breast cancer brain metastasis (BCBM) and leptomeningeal disease (LMD). Improvements in systemic...
17.
Law V, Chen Z, Vena F, Smalley I, MacAulay R, Evernden B, et al.
Neuro Oncol
. 2022 Feb;
24(10):1673-1686.
PMID: 35213727
Background: Leptomeningeal disease (LMD) occurs as a late complication of several human cancers and has no rationally designed treatment options. A major barrier to developing effective therapies for LMD is...
18.
Pina Y, Yadugiri S, Yeboa D, Ferguson S, Forsyth P, Glitza Oliva I
Curr Oncol Rep
. 2022 Jan;
24(1):43-54.
PMID: 35059999
Purpose Of Review: Melanoma has one of the highest incidences of causing leptomeningeal disease (LMD) among solid tumors. LMD patients have very poor prognosis with a dismal survival despite aggressive...
19.
Ahmed K, Kim Y, Arrington J, Kim S, Dejesus M, Soyano A, et al.
Adv Radiat Oncol
. 2021 Dec;
6(6):100798.
PMID: 34934864
Purpose: We hypothesize treatment with nivolumab and stereotactic radiosurgery (SRS) will be feasible and well tolerated, and may improve intracranial tumor control rates compared with SRS alone. Methods And Materials:...
20.
Basu A, Albert G, Awshah S, Datta J, Kodumudi K, Gallen C, et al.
Cancer Immunol Res
. 2021 Nov;
10(1):108-125.
PMID: 34785506
The HER3/ERBB3 receptor is an oncogenic receptor tyrosine kinase that forms heterodimers with EGFR family members and is overexpressed in numerous cancers. HER3 overexpression associates with reduced survival and acquired...